Chelation and mobilization of cellular iron by different classes of chelators

Molecular Pharmacology

Volumn 51, Issue 5, 1997, Pages 842-852

  Zanninelli, G ^a,b   Glickstein, H ^a   Breuer, W ^a   Milgram, P ^a   Brissot, P ^b   Hider, R C ^c   Konijn, A M ^d   Libman, J ^e   Shanzer, A ^e   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HEBREW UNIVERSITY   (Israel)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; 2 ETHYL 3 HYDROXY 1 (2 HYDROXYETHYL) 4 PYRIDINONE; 3 HYDROXY 1 (3 HYDROXYPROPYL) 2 METHYL 4 PYRIDINONE; CALCEIN; CHELATING AGENT; CP 165; CP 40; DEFERIPRONE; DEFEROXAMINE; HYDROXYUREA; SIDEROPHORE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; IRON CHELATION; IRON KINETICS; IRON TRANSPORT; LIPOPHILICITY; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; TRANSPORT KINETICS;

EID: 18344410299     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.5.842     Document Type: Article

References (21)

1. Hershko, C., and D. J. Weatherall. Iron-chelating therapy. Crit. Rev. Clin. Lab. Sci. 26:303-345 (1988).
2. Hershko, C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators, in Bailliere's Clinical Haematology: Clinical Disorders of Iron Metabolism (C. Hershko, ed.). Bailliere Tindall, London, 965-1000 (1994).
3. Nathan, D. G., and Piomelli S. Introduction: oral iron chelators. Semin. Haematol. 27:83-85 (1990).
4. Hershko, C., A. Pinson, and G. Link. Iron chelation. Blood Rev. 4:1-8 (1990).
5. Brittenham, G. M. Development of iron chelating agents for clinical use. Blood 80:569-574 (1992).
6. Hider, R. C., and S. Singh. Iron chelating agents with clinical potential. Proc. R. Soc. Edinb. Sect. B (Biol.) 99:137-168 (1992).
7. Porter, J. B., M. Gyparaky, L. C. Burke, E. R. Huehns, P. Sarpong, V. Saez, and R. C. Hider. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and iron-binding constant. Blood 72:1497-1503 (1988).
8. Porter, J. B., R. C. Hider, and E. R. Heuhns. Update on the hydropyridone oral iron-chelating agents. Semin. Hematol. 27:95-100 (1990).
9. Shanzer, A., J. Libman, H. Glickstein, S. D. Lytton, and Z. I. Cabantchik. Reversed siderophores act as antimalarial agent. Proc. Natl. Acad. Sci. USA 88:6585-6589 (1991).
10. Loyevsky, M., J. Lytton, B. Mester, J. Libman, A. Shanzer, and Z. I. Cabantchik. The antimalarial action of desferal involves a direct access route to erythrocytic (P falciparum) parasites. J. Clin. Invest. 91:218-224 (1993).
11. Breuer, W., S. Epsztejn, and Z. I. Cabantchik. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J. Biol. Chem. 270:24209-24215 (1995).
12. Cabantchik, Z. I., H. Glickstein, P. Milgram, and W. Breuer. A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells. Anal. Biochem. 233:221-227 (1996).
13. Dobbin, P. S., R. C. Hider, A. D. Hall, P. D. Taylor, P. Sarpong, J. B. Porter, and G. Xiao. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4 (1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 36:2448-2458 (1993).
14. Tsafack, J., J. Golenser, J. Libman, A. Shanzer, and Z. I. Cabantchik. Mode of action of iron(III) chelators as antimalarials. III. Overadditive effects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum. Mol. Pharmacol. 47:403-409 (1995).
15. Ponka, P., R. W. Grady, A. Wilczynska, and H. M. Schulman. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim. Biophys. Acta 802:477-489 (1984).
16. Dayan J, J. Libman, Y. Agi, and A. Shanzer. Chiral siderophores analogs: ferrichrome I. Inorg. Chem. 32:1467-1475. (1993).
17. Porter, J. B., E. R. Huehns, and R. C. Hider. The development of iron chelating drugs. Bailliere's Clin. Haematol. 2:257-292 (1989).
18. Zanninelli, G., J. B. Porter, O. Loreal, G. Lescoat, B. Cosson, R. Verna, and P. Brissot. Biliary excretion of plasma NTBI in the rat is enhanced by the novel hydroxypyrid-4-one oral chelators. Hepatology 22: 309A (1995).
19. Kontoghiorghes, G., and A. V. Hoffbrand. Orally active α-ketohydroxy-pyridine iron chelators intended for clinical use: in vivo studies in rabbit. Br. J. Haematol. 62:607-613. (1986).
20. Glickstein, H., W. Breuer, M. Loyevsky, A. M. Konijn, J. Libman, A. Shanzer, and Z. I. Cabantchik. Differential cytotoxicity of iron chelators on malaria infected cells versus mammalian cells. Blood 87:4871-4878 (1996).
21. Lytton, S. J., B. Mester, H. Glickstein, I. Dayan, J. Libman, A. Shanzer, and Z. I. Cabantchik. Mode of action of iron(III) chelators as antimalaria agents II: evidence for differential effects on parasite-dependent nucleic acid synthesis. Blood 84:910-915 (1994).